Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Free Report)’s stock price was down 7.9% during mid-day trading on Tuesday . The stock traded as low as $1.08 and last traded at $1.08. Approximately 979 shares were traded during trading, a decline of 51% from the average daily volume of 2,009 shares. The stock had previously closed at $1.17.
Kiromic BioPharma Price Performance
The company has a fifty day moving average of $1.20 and a 200-day moving average of $1.19. The firm has a market capitalization of $1.52 million, a PE ratio of -0.28 and a beta of 1.66.
About Kiromic BioPharma
Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.
Further Reading
- Five stocks we like better than Kiromic BioPharma
- ETF Screener: Uses and Step-by-Step Guide
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- How to Capture the Benefits of Dividend Increases
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
